Kancera AB (publ) - Asset Resilience Ratio
Kancera AB (publ) (KAN) has an Asset Resilience Ratio of 65.98% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Kancera AB (publ) carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Kancera AB (publ)'s Asset Resilience Ratio has changed over time. See KAN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kancera AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kancera AB (publ) (KAN) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr37.34 Million | 65.98% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr37.34 Million | 65.98% |
Asset Resilience Insights
- Very High Liquidity: Kancera AB (publ) maintains exceptional liquid asset reserves at 65.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Kancera AB (publ) Industry Peers by Asset Resilience Ratio
Compare Kancera AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Kancera AB (publ) (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Kancera AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.29% | Skr46.36 Million ≈ $4.99 Million |
Skr66.91 Million ≈ $7.20 Million |
-0.32pp |
| 2023-12-31 | 69.61% | Skr45.69 Million ≈ $4.92 Million |
Skr65.64 Million ≈ $7.06 Million |
-9.20pp |
| 2022-12-31 | 78.81% | Skr95.15 Million ≈ $10.24 Million |
Skr120.74 Million ≈ $12.99 Million |
-1.04pp |
| 2021-12-31 | 79.85% | Skr106.52 Million ≈ $11.46 Million |
Skr133.41 Million ≈ $14.36 Million |
+13.65pp |
| 2020-12-31 | 66.19% | Skr55.01 Million ≈ $5.92 Million |
Skr83.10 Million ≈ $8.94 Million |
+39.48pp |
| 2019-12-31 | 26.71% | Skr11.85 Million ≈ $1.28 Million |
Skr44.35 Million ≈ $4.77 Million |
-19.46pp |
| 2018-12-31 | 46.17% | Skr21.02 Million ≈ $2.26 Million |
Skr45.53 Million ≈ $4.90 Million |
-8.05pp |
| 2017-12-31 | 54.22% | Skr27.77 Million ≈ $2.99 Million |
Skr51.23 Million ≈ $5.51 Million |
-24.87pp |
| 2016-12-31 | 79.09% | Skr57.76 Million ≈ $6.22 Million |
Skr73.03 Million ≈ $7.86 Million |
+78.92pp |
| 2011-12-31 | 0.17% | Skr67.00K ≈ $7.21K |
Skr39.74 Million ≈ $4.28 Million |
-- |
About Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more